

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-293001	Application No. 09/668,196
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Stephen J. Russell et al.	
		Filing Date September 22, 2000	Group Art Unit 1648

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AC	Heinzerling et al., "Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells," <i>Blood</i> , 106:2287-2294 (2005)
	AD	Myers et al., "Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer," <i>Cancer Gene Therapy</i> , 12:593-599 (2005)
	AE	Ong et al., "Oncolytic Measles Virus Targets High CD46 Expression on Multiple Myeloma Cells," Manuscript submitted for publication in <i>Experimental Hematology</i> on November 30, 2005 (27 pages)
	AF	Peng et al., "Systemic therapy of myeloma xenografts by an attenuated measles virus," <i>Blood</i> , 98:2002-2007 (2001)
	AG	Peng et al., "Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus," <i>Cancer Research</i> , 62:4656-4662 (2002)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	